We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Cisatracurium Besylate Injection

News List

Meitheal Recalls Cisatracurium Besylate Injection americanpharmaceuticalreview
February 01, 2021
Meitheal Pharmaceuticals is voluntarily recalling one (1) lot of Cisatracurium Besylate Injection, USP 10mg per 5mL to the user level.
Zydus Cadila Receives FDA Approval for Cisatracurium Besylate Injection americanpharmaceuticalreview
September 07, 2020
Zydus Cadila has received final approval from the US Food and Drug Administration (FDA) to market Cisatracurium Besylate Injection USP (US RLD: Nimbex ®) in the strength of 20 mg (base)/10 mL (2 mg/mL) Multiple-Dose Vial.
Zydus Cadila gets US FDA approval for Cisatracurium Besylate Injection expresspharma
September 03, 2020
Zydus Cadila has received final approval from the USFDA to market Cisatracurium Besylate Injection USP (US RLD: Nimbex) in the strength of 20 mg (base)/10 mL (2 mg/mL) multiple-dose vial.